Patient characteristics according to prevaccination COVID-19
| Characteristics . | Prior COVID-19 (n = 99) . | Control cohort (n = 362) . | P . |
|---|---|---|---|
| Prior COVID-19 | |||
| Diagnosed by PCR | 82 (82) | ||
| Positive serostatus prior to vaccination | 33 (41) | ||
| Negative serostatus prior to vaccination | 18 (22) | ||
| Detected by prevaccine serological test | 17 (30) | ||
| Asymptomatic infection | 16 (16) | ||
| URTD symptoms | 19 (19) | ||
| LRTD symptoms | 76 (76) | ||
| Oxygen requirement | 18 (18) | ||
| ICU admission | 5 (5) | ||
| Time from COVID-19 to vaccination, median (range), d | 185 (33-422) | ||
| Serological status prior to vaccination | NT | ||
| Positive | 50 (50) | 0 | |
| Negative | 18 (18) | 362 (100) | |
| NT | 31 (31) | 0 | |
| Time from serology to vaccination, median (range), d | 0 (0-330) | 0 (0-14) | .6 |
| Type of vaccine | .001 | ||
| Moderna mRNA-1273 | 76 (76) | 328 (90) | |
| Pfizer-BioNTech BNT162b2 | 22 (22) | 30 (8) | |
| Adenoviral vector based | 1 (1) | 4 (1) | |
| Age, y | .84 | ||
| Median (range) | 59 (20-88) | 59 (18-88) | |
| 18-40 | 6 (6) | 66 (18) | |
| 41-50 | 19 (19) | 45 (12) | |
| 51-60 | 26 (26) | 73 (20) | |
| 61-70 | 26 (26) | 110 (31) | |
| >71 | 22 (22) | 68 (19) | |
| Males | 56 (56) | 203 (56) | .99 |
| Baseline disease | .06 | ||
| AL/MDS | 25 (25) | 141 (39) | |
| B-cell NHL | 21 (21) | 69 (19) | |
| MM | 15 (15) | 45 (12) | |
| CLL | 17 (17) | 31 (9) | |
| HD | 6 (6) | 36 (10) | |
| MPN | 11 (11) | 29 (8) | |
| Others | 4 (4) | 11 (3) | |
| Type of stem cell transplant | .01 | ||
| Allo-HSCT | 29 (29) | 186 (51) | |
| ASCT | 6 (6) | 24 (7) | |
| Disease status at vaccination | .001 | ||
| Complete remission | 59 (59) | 264 (73) | |
| Partial remission | 16 (16) | 19 (5) | |
| Not in response | 20 (20) | 51 (14) | |
| First-line therapy | 4 (4) | 28 (8) | |
| Treatment given during vaccination | 39 (39) | 119 (43) | .5 |
| Treatment planned after vaccination | 38 (38) | 98 (27) | .05 |
| Time from last treatment to COVID-19 vaccine | .03 | ||
| Untreated | 16 (16) | 30 (8) | |
| Active treatment | 39 (39) | 119 (33) | |
| ≥6 mo to 1 y | 6 (6) | 25 (7) | |
| ≥1 y | 37 (37) | 187 (52) | |
| Immunosuppressant drugs at vaccination | 22 (22) | 81 (22) | .3 |
| Corticosteroids at vaccination | 16 (16) | 52 (14) | .6 |
| Daratumumab | 5 (5) | 13 (4) | .6 |
| Venetoclax | 3 (3) | 6 (2) | .4 |
| Anti-CD20 mAb | 19 (19) | 56 (15) | .9 |
| BTKI therapy | 10 (10) | 17 (5) | .05 |
| Other TKI therapy | 2 (2) | 12 (3) | .7 |
| Lenalidomide maintenance | 6 (6) | 23 (6) | .99 |
| Ruxolitinib therapy | 4 (4) | 6 (2) | .3 |
| Blood count before vaccination (×109/mL) | |||
| Absolute neutrophil count, median (range) | 3.08 (0.72-31.0) | 3.03 (.06-22.1) | .9 |
| Absolute lymphocyte count, median (range) | 1.91 (0.5-41.3) | 1.82 (0.28-194.2) | .6 |
| Absolute lymphocyte count < 1 × 109/mL | 9 (9) | 54 (15) | .2 |
| Time from second dose to serology, median (range), d | 21 (14-51) | 21 (14-57) | .8 |
| Time between vaccine doses, median (range), d | 28 (18-91) | 28 (19-91) | .78 |
| SCoV2-R-A detection at 3 wk after full vaccination | 92 (93) | 281 (78) | <.0001 |
| Follow-up after complete vaccination, median (range), d | 28 (15-109) | 27 (16-89) | .9 |
| COVID-19 after vaccination | 0 | 2 (0.6) | .99 |
| Characteristics . | Prior COVID-19 (n = 99) . | Control cohort (n = 362) . | P . |
|---|---|---|---|
| Prior COVID-19 | |||
| Diagnosed by PCR | 82 (82) | ||
| Positive serostatus prior to vaccination | 33 (41) | ||
| Negative serostatus prior to vaccination | 18 (22) | ||
| Detected by prevaccine serological test | 17 (30) | ||
| Asymptomatic infection | 16 (16) | ||
| URTD symptoms | 19 (19) | ||
| LRTD symptoms | 76 (76) | ||
| Oxygen requirement | 18 (18) | ||
| ICU admission | 5 (5) | ||
| Time from COVID-19 to vaccination, median (range), d | 185 (33-422) | ||
| Serological status prior to vaccination | NT | ||
| Positive | 50 (50) | 0 | |
| Negative | 18 (18) | 362 (100) | |
| NT | 31 (31) | 0 | |
| Time from serology to vaccination, median (range), d | 0 (0-330) | 0 (0-14) | .6 |
| Type of vaccine | .001 | ||
| Moderna mRNA-1273 | 76 (76) | 328 (90) | |
| Pfizer-BioNTech BNT162b2 | 22 (22) | 30 (8) | |
| Adenoviral vector based | 1 (1) | 4 (1) | |
| Age, y | .84 | ||
| Median (range) | 59 (20-88) | 59 (18-88) | |
| 18-40 | 6 (6) | 66 (18) | |
| 41-50 | 19 (19) | 45 (12) | |
| 51-60 | 26 (26) | 73 (20) | |
| 61-70 | 26 (26) | 110 (31) | |
| >71 | 22 (22) | 68 (19) | |
| Males | 56 (56) | 203 (56) | .99 |
| Baseline disease | .06 | ||
| AL/MDS | 25 (25) | 141 (39) | |
| B-cell NHL | 21 (21) | 69 (19) | |
| MM | 15 (15) | 45 (12) | |
| CLL | 17 (17) | 31 (9) | |
| HD | 6 (6) | 36 (10) | |
| MPN | 11 (11) | 29 (8) | |
| Others | 4 (4) | 11 (3) | |
| Type of stem cell transplant | .01 | ||
| Allo-HSCT | 29 (29) | 186 (51) | |
| ASCT | 6 (6) | 24 (7) | |
| Disease status at vaccination | .001 | ||
| Complete remission | 59 (59) | 264 (73) | |
| Partial remission | 16 (16) | 19 (5) | |
| Not in response | 20 (20) | 51 (14) | |
| First-line therapy | 4 (4) | 28 (8) | |
| Treatment given during vaccination | 39 (39) | 119 (43) | .5 |
| Treatment planned after vaccination | 38 (38) | 98 (27) | .05 |
| Time from last treatment to COVID-19 vaccine | .03 | ||
| Untreated | 16 (16) | 30 (8) | |
| Active treatment | 39 (39) | 119 (33) | |
| ≥6 mo to 1 y | 6 (6) | 25 (7) | |
| ≥1 y | 37 (37) | 187 (52) | |
| Immunosuppressant drugs at vaccination | 22 (22) | 81 (22) | .3 |
| Corticosteroids at vaccination | 16 (16) | 52 (14) | .6 |
| Daratumumab | 5 (5) | 13 (4) | .6 |
| Venetoclax | 3 (3) | 6 (2) | .4 |
| Anti-CD20 mAb | 19 (19) | 56 (15) | .9 |
| BTKI therapy | 10 (10) | 17 (5) | .05 |
| Other TKI therapy | 2 (2) | 12 (3) | .7 |
| Lenalidomide maintenance | 6 (6) | 23 (6) | .99 |
| Ruxolitinib therapy | 4 (4) | 6 (2) | .3 |
| Blood count before vaccination (×109/mL) | |||
| Absolute neutrophil count, median (range) | 3.08 (0.72-31.0) | 3.03 (.06-22.1) | .9 |
| Absolute lymphocyte count, median (range) | 1.91 (0.5-41.3) | 1.82 (0.28-194.2) | .6 |
| Absolute lymphocyte count < 1 × 109/mL | 9 (9) | 54 (15) | .2 |
| Time from second dose to serology, median (range), d | 21 (14-51) | 21 (14-57) | .8 |
| Time between vaccine doses, median (range), d | 28 (18-91) | 28 (19-91) | .78 |
| SCoV2-R-A detection at 3 wk after full vaccination | 92 (93) | 281 (78) | <.0001 |
| Follow-up after complete vaccination, median (range), d | 28 (15-109) | 27 (16-89) | .9 |
| COVID-19 after vaccination | 0 | 2 (0.6) | .99 |
Unless noted otherwise, data are n (%).
AL/MDS, acute leukemia/myelodysplastic syndrome; allo-HSCT, allogeneic hematopoietic stem cell transplantation; ASCT, autologous stem cell transplantation; BTKI, Bruton’s tyrosine kinase inhibitor; CLL, chronic lymphocytic leukemia; HD, Hodgkin disease; ICU, intensive care unit; LRTD, lower respiratory tract disease; mAb, monoclonal antibody; MM, multiple myeloma; MPN, chronic myeloproliferative neoplasm; NT, not tested; TKI, tyrosine kinase inhibitor; URTD, upper respiratory tract disease.